AG00ILMS

80621-81-4 | 2,7-(Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione,25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-,(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-

AG00ILMS

SDS

COA

TIP This product is typically in stock.Please contact us for quotation.

Request For Quotation

• mg
• g
• kg
• ml
• L

无数据

• mg
• g
• kg
• ml
• L

无数据

无数据

Inquire

CAS Number	80621-81-4
Catalog Number	AG00ILMS(AGN-PC-0UHD0Q)
Chemical Name	2,7-(Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione,25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-,(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-
EC Number	617-130-4
IUPAC Name	[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.14,7.05,35.026,34.027,32]heptatriaconta-1(35),2,4,9,19,21,25(36),26(34),28,30,32-undecaen-13-yl] acetate
InChI	InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1
InChI Key	NZCRJKRKKOLAOJ-XRCRFVBUSA-N
MDL Number	MFCD00864973
Molecular Formula	C43H51N3O11
Molecular Weight	785.8785
SMILES	O=C1c2c3c4c(n5c(n4)cc(cc5)C)c4c(c3c(c(c2O[C@]1(C)O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(=O)C)[C@H](C)[C@H](O)[C@H](C)[C@H]([C@H](/C=C/C=C(C(=O)N4)/C)C)O)C)O)O
UNII	L36O5T016N
Synonyms	4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin, L 105, L-105, L105, Redactiv, rifaximin, Xifaxan, Rifaximin, Rifaxidin, Rifacol, Xifaxan, Rifaximine, Rifamycin L 105, 80621-81-4, Rifamycin L 105SV, Fatroximin, Rifaximina, Normix, Rifamixin, Rifaximinum, Ritacol, Rifaximine [French], Rifaximinum [Latin], Rifaximina [Spanish], Rifaximin [USAN:INN], UNII-L36O5T016N, L 105SV, L 105 (Ansamacrolide antibiotic), L 105, C43H51N3O11, BRN 3584528, CHEBI:75246, L36O5T016N, MFCD00864973, Rifaximin (Xifaxan), Rifaximin, 98%, 4-Deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4-c)rifamycin SV, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26S,27S,28E)-5,6,21,23,25 Pentahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2H)-dione, 25-acetate, Rifaxin, RedActiv, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-1,15-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)furo[2'',3'':7',8']naphtho[1',2':4,5]imidazo[1,2-a]pyridin-25-yl acetate, 2,7-(Epoxypentadeca(1,11,13)trienimino)benzofuro(4,5-e)pyrido(1,2-a)benzimidazole-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, (2S-(2R*,16Z,18E,20R*,21R*,22S*,23S*,24S*,25R*,26S*,27R*,28E))-, rifaximinun, Flonorm, Lumenax, Spiraxin, Xifaxsan, Lormyx, Rifaximin [USAN:INN:BAN], 4-Deoxy-4'-methylpyrido[1',2'-1,2]imidazo[5,4-c]rifamycin SV, NCGC00095842-01, Xifaxan (TN), Rifacol;Fatroximin;Xifaxan, alpha-0817185, CHEMBL1617, DSSTox_CID_25998, DSSTox_RID_81280, DSSTox_GSID_45998, Rifaximin (JAN/USAN/INN), SCHEMBL124066, DTXSID7045998, NZCRJKRKKOLAOJ-XRCRFVBUSA-N, 4-deoxy-4'-methylpyrido(1',2'-1,2)imidazo(5,4C)rifamycin, HMS3715B19, 88747-56-2, Tox21_111529, BDBM50347620, s1790, AKOS015963053, ZINC169621200, CCG-221129, DB01220, ido[1,2-a]benzimidazol-25-yl acetate, AC-19112, AN-36430, BC208535, H732, LS-64147, AB2000295, CAS-80621-81-4, LS-178059, D02554, J10371, AB01209738-01, AB01209738-03, AB01209738_04, Rifaximin, Antibiotic for Culture Media Use Only, 621R814, Q-201671, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)5,6,21,23-Tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-1,15-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)[1]benzofuro[4,5-e]pyr, (7S,11S,12R,13S,14R,15R,16R,17S,18S)-2,15,17,36-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22,30-octamethyl-6,23-dioxo-8,37-dioxa-24,27,33-triazahexacyclo[23.10.1.1;{4,7}.0;{5,35}.0;{26,34}.0;{27,32}]heptatriaconta-1,3,5(35),9,19,21,25(36),26(34),28,30,32-undecaen-13-yl acetate, refaximin, Xifaxanta, duplicate RN, RCIFAX, Unable to generate value, D04ITO, L-105, ACN-039933, C43-H51-N3-O11, CID6436173, CS-O-02226, L105, C042734, D000078262, Rifaximin (bioadhesive/ gastrointestinal extended release), 4-deoxy-4'-methylpyrido[1',2'-1,2]-nu-imidazo[5,4-c]rifamycin SV, Rifaximin (bioadhesive/ gastrointestinal extended release), Salix Pharmaceuticals, 2,7-(Epoxy(1,11,13)pentadecatrienoimino)furo(2'',3'':7',8')naphth(1',2':4,5)imidazo(1,2-a)pyridine-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, ( 2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-, 2,7-(Epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-,

Complexity	1590
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	9
Defined Bond Stereocenter Count	3
Exact Mass	785.352g/mol
Formal Charge	0
Heavy Atom Count	57
Hydrogen Bond Acceptor Count	12
Hydrogen Bond Donor Count	5
Isotope Atom Count	0
Molecular Weight	785.891g/mol
Monoisotopic Mass	785.352g/mol
Rotatable Bond Count	3
Topological Polar Surface Area	198A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	6.9

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class
Hazard statements	H302-H315-H319-H335
Packing Group
Precautionary statements	P261-P305+P351+P338
UN Code

Certificate of Analysis

Lot Number